UPDATE: Mizuho Initiates Coverage On CytomX With Buy, $16 Target As Firm Believes Co's 'Overhangs are Real but can go Away' As Firm Thinks CX-072 Is Underestimated, 'CX-2009 Down but not Out', And 'Partnered Programs are Still Part of the Story'

Never miss a trade again with the fastest news alerts in the world!

This headline only article is a sample of real-time intelligence Benzinga Pro traders use to win in the markets everyday.

Want the fastest, most accurate stock market intelligence? Want EXCLUSIVE stories originated by Benzinga reporters? Join 10,000+ serious traders in the Benzinga Pro community!